Literature DB >> 17380060

Is cystic fibrosis carrier screening cost effective?

S Wei1, M H Quigg, K G Monaghan.   

Abstract

Between 2001 and 2005, 6,166 females underwent cystic fibrosis (CF) carrier screening at our institution. Only 36% were Caucasian. We identified 143 carrier females and subsequently tested 85 of their partners. The observed carrier frequency was not significantly different than expected for any racial or ethnic group tested. We identified 6 positive couples (5 Caucasian, 1 Arab American) and 1 affected fetus. In just under 4 years, our institution spent approximately $334,000 on CF population screening. Comparing this to the lifetime medical cost for a CF patient, CF population-based carrier screening is cost effective at our institution, despite the high number of non-Caucasians being screened. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380060     DOI: 10.1159/000099088

Source DB:  PubMed          Journal:  Community Genet        ISSN: 1422-2795


  3 in total

1.  Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis.

Authors:  Subhashini Chandrasekharan; Christopher Heaney; Tamara James; Chris Conover; Robert Cook-Deegan
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.822

2.  An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals.

Authors:  Gabriel A Lazarin; Imran S Haque; Shivani Nazareth; Kevin Iori; A Scott Patterson; Jessica L Jacobson; John R Marshall; William K Seltzer; Pasquale Patrizio; Eric A Evans; Balaji S Srinivasan
Journal:  Genet Med       Date:  2012-09-13       Impact factor: 8.822

3.  Cost-effectiveness of the CFTR gene-sequencing test for asymptomatic carriers in the Colombian population

Authors:  Ernesto Andrade; Jorge Díaz
Journal:  Biomedica       Date:  2020-06-15       Impact factor: 0.935

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.